New data on Chiesi COPD fixed ICS/LABA/LAMA combination treatment

3 September 2016

Positive results from the TRILOGY study have been published in the special ERS edition of the prestigious medical journal The Lancet and will also be presented on September 4 at the European Respiratory Society (ERS) Congress in London.

The study provided for the first time one year evidence that an extrafine formulation of a fixed ICS/LABA/LAMA triple combination - developed by Italian family-owned drugmaker Chiesi Farmaceutici - is superior to the fixed dose ICS/LABA combined therapy (one of the standard treatments for chronic obstructive pulmonary disease; COPD) regarding a series of clinical efficacy parameters, and demonstrates an acceptable safety profile. More specifically compared to the ICS/LABA dual combination, the new triple fixed combination:

Reduces the annual incidence of exacerbations, events that are the most threatening for patients and the main cause of hospitalization and even death resulting in high costs for the healthcare system;
Improves significantly pulmonary function; and
Reduces breathlessness (dyspnea) and improves patient’s symptom profile

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK